Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia (TDT) or Sickle Cell Disease (SCD): Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs)
- Resource Type
- Source
- Transplantation and Cellular Therapy. 27:S72-S73
- Subject
Transplantation business.industry Thalassemia Cell CD34 Cell Biology Hematology Disease medicine.disease Haematopoiesis medicine.anatomical_structure Immunology Molecular Medicine Immunology and Allergy Medicine CRISPR In patient Progenitor cell business - Language
- ISSN
- 2666-6367